论文部分内容阅读
Ⅲ期结直肠癌(CRC)患者的生存率易变化且难以预测。肿瘤大小不是CRC分期系统的一部分,也不用于对生存率的预测,但美国Poritz LS等猜测它可用于预测CRC的无瘤生存期。因此,Poritz LS等收集了63例Ⅲ期CRC患者的临床资料,计算每例患者肿瘤体积与阳性淋巴结百分比的比值(TN比),并根据患者术后5年的转移情况,将患者分为转移组(n=28)和无
Survival rates in patients with stage III colorectal cancer (CRC) are variable and unpredictable. Tumor size is not part of the CRC staging system nor is it used to predict survival, but Poritz LS et al. (US) speculate that it can be used to predict the disease-free survival of CRC. Therefore, Poritz LS, etc. collected 63 cases of stage Ⅲ CRC patients with clinical data, calculate the tumor volume and the percentage of positive lymph nodes for each ratio (TN ratio), and according to the patients after 5 years of metastasis, the patients were divided into metastasis Group (n = 28) and none